United Therapeutics (UTHR) 10-Q 29 Jul 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 21, 2014
Document and Entity Information	'	'
Entity Registrant Name	'UNITED THERAPEUTICS Corp	'
Entity Central Index Key	'0001082554	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	47,269,381
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$259,046	$278,889
Marketable investments	308,534	409,645
Accounts receivable, net of allowance of none for 2014 and 2013	212,902	126,297
Inventories, net	58,033	47,758
Other current assets	43,093	46,424
Total current assets	881,608	909,013
Marketable investments	280,887	448,134
Goodwill and other intangibles, net	15,336	14,115
Property, plant and equipment, net	477,534	464,950
Deferred tax assets, net	193,808	192,718
Other assets	103,699	58,637
Total assets	1,952,872	2,087,567
Current liabilities:	'	'
Accounts payable and accrued expenses	112,246	92,244
Convertible notes	221,712	215,845
Share tracking awards plan	164,427	287,956
Line of credit and mortgages payable-current	141,614	66,614
Other current liabilities	19,074	25,015
Total current liabilities	659,073	687,674
Other liabilities	80,724	95,582
Total liabilities	739,797	783,256
Commitments and contingencies:	'	'
Temporary equity	39,170	45,037
Stockholders' equity:	'	'
Common stock, par value $.01, 245,000,000 shares authorized, 63,756,923 and 63,013,192 shares issued, and 47,230,528 and 50,388,140 shares outstanding at June 30, 2014 and December 31, 2013, respectively	638	630
Additional paid-in capital	1,101,476	1,057,224
Accumulated other comprehensive loss	-14,627	-13,183
Treasury stock at cost, 16,526,395 and 12,625,052 shares at June 30, 2014 and December 31, 2013, respectively	-890,998	-513,437
Retained earnings	977,416	728,040
Total stockholders' equity	1,173,905	1,259,274
Total liabilities and stockholders' equity	1,952,872	2,087,567
Preferred Stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued	'	'
Series A Junior Participating Preferred Stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued	'	'

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Accounts receivable, allowance (in dollars)	$0	$0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	245,000,000	245,000,000
Common stock, shares issued	63,756,923	63,013,192
Common stock, shares outstanding	47,230,528	50,388,140
Treasury stock, shares	16,526,395	12,625,052
Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Series A Junior Participating Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:	'	'	'	'
Net product sales	$321,329	$277,495	$605,882	$520,641
Other	1,473	3,111	6,323	5,101
Total revenues	322,802	280,606	612,205	525,742
Operating expenses:	'	'	'	'
Research and development	39,742	54,617	52,190	105,047
Selling, general and administrative	68,031	71,365	98,246	142,721
Cost of product sales	38,709	32,320	69,309	61,633
Total operating expenses	146,482	158,302	219,745	309,401
Operating income	176,320	122,304	392,460	216,341
Other (expense) income:	'	'	'	'
Interest income	1,110	869	2,343	1,848
Interest expense	-4,746	-4,520	-9,356	-8,956
Other, net	349	-134	802	121
Total other (expense) income, net	-3,287	-3,785	-6,211	-6,987
Income before income taxes	173,033	118,519	386,249	209,354
Income tax expense	-61,181	-38,655	-136,873	-67,165
Net income	$111,852	$79,864	$249,376	$142,189
Net income per common share:	'	'	'	'
Basic (in dollars per share)	$2.35	$1.60	$5.09	$2.84
Diluted (in dollars per share)	$2.10	$1.52	$4.54	$2.71
Weighted average number of common shares outstanding:	'	'	'	'
Basic (in shares)	47,617	49,800	49,002	50,003
Diluted (in shares)	53,252	52,648	54,948	52,386

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME	'	'	'	'
Net income	$111,852	$79,864	$249,376	$142,189
Other comprehensive income (loss):	'	'	'	'
Foreign currency translation gain (loss)	859	-373	382	-2,663
Defined benefit pension plan:	'	'	'	'
Prior service cost arising during period, net of tax	'	'	-2,415	'
Actuarial gain arising during period, net of tax	'	'	221	51
Less: amortization of actuarial gain and prior service cost included in net periodic pension cost, net of tax	226	256	452	512
Total defined benefit pension plan, net	226	256	-1,742	563
Unrealized loss on available-for-sale securities, net of tax	-70	-35	-84	-58
Other comprehensive gain (loss), net of tax	1,015	-152	-1,444	-2,158
Comprehensive income	$112,867	$79,712	$247,932	$140,031

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net income	$249,376	$142,189
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	15,206	15,845
Provision for inventory obsolescence	1,453	142
Current and deferred income tax expense	136,873	67,165
Share-based compensation (benefit) expense	-62,596	68,199
Amortization of debt discount and debt issue costs	6,532	6,240
Amortization of discount or premium on investments	2,988	2,038
Other	-414	1,313
Excess tax benefits from share-based compensation	-14,040	-2,634
Changes in operating assets and liabilities:	'	'
Accounts receivable	-86,473	-15,455
Inventories	-11,266	-7,705
Other assets	731	4,085
Accounts payable and accrued expenses	20,017	6,763
Other liabilities	-202,270	-106,639
Net cash provided by operating activities	56,117	181,546
Cash flows from investing activities:	'	'
Purchases of property, plant and equipment	-31,512	-9,080
Purchases of held-to-maturity investments	-110,095	-162,461
Cost-method investments	-45,000	-30,766
Maturities of held-to-maturity investments	375,164	239,511
Net cash provided by investing activities	188,557	37,204
Cash flows from financing activities:	'	'
Payments to repurchase common stock	-377,562	-42,438
Proceeds from line of credit	75,000	'
Proceeds from the exercise of stock options	22,171	10,097
Issuance of stock under employee stock purchase plan	1,672	1,318
Excess tax benefits from share-based compensation	14,040	2,634
Net cash used in financing activities	-264,679	-28,389
Effect of exchange rate changes on cash and cash equivalents	162	-841
Net increase in cash and cash equivalents	-19,843	189,520
Cash and cash equivalents, beginning of period	278,889	154,030
Cash and cash equivalents, end of period	259,046	343,550
Supplemental schedule of cash flow information:	'	'
Cash paid for interest	2,727	2,775
Cash paid for income taxes	140,366	85,649
Non-cash investing activity:	'	'
Non-cash additions to property, plant and equipment	$4,429	$2,685

Organization_and_Business_Desc

Organization and Business Description	6 Months Ended
	Jun. 30, 2014
Organization and Business Description	'
Organization and Business Description	'
	1. Organization and Business Description
	United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. As used in these notes to the consolidated financial statements, unless the context otherwise requires, the terms “we”, “us”, “our,” and similar terms refer to United Therapeutics Corporation and its consolidated subsidiaries.
	We have approval from the United States Food and Drug Administration (FDA) to market the following therapies: Remodulin® (treprostinil) Injection (Remodulin), Tyvaso® (treprostinil) Inhalation Solution (Tyvaso), Adcirca® (tadalafil) Tablets (Adcirca) and Orenitram® (treprostinil) Extended-Release Tablets (Orenitram). We commenced commercial sales of Orenitram during the second quarter of 2014. Remodulin has also been approved in various countries outside the United States.

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Basis of Presentation	'
Basis of Presentation	'
	2. Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all of the information required by United States generally accepted accounting principles (GAAP) for complete financial statements. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC on February 25, 2014.
	In our management’s opinion, the accompanying consolidated financial statements contain all adjustments, including normal, recurring adjustments, necessary to fairly present our financial position as of June 30, 2014, results of operations and comprehensive income for the three- and six-month periods ended June 30, 2014 and 2013, and cash flows for the six-month periods ended June 30, 2014 and 2013. Interim results are not necessarily indicative of results for an entire year.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventories	'
Inventories	'
	3. Inventories
	Inventories are stated at the lower of cost (first-in, first-out method) or market (current replacement cost) and consist of the following, net of reserves (in thousands):
		June 30,		December 31,
		2014		2013
	Raw materials	$	23,651	$	18,377
	Work-in-progress	12,027		11,802
	Finished goods	22,355		17,579
	Total inventories	$	58,033	$	47,758

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements	'
Fair Value Measurements	'
	4. Fair Value Measurements
	Assets and liabilities subject to fair value measurements are required to be disclosed within a fair value hierarchy. The fair value hierarchy ranks the quality and reliability of inputs used to determine fair value. Accordingly, assets and liabilities carried at, or permitted to be carried at, fair value are classified within the fair value hierarchy in one of the following categories based on the lowest level input that is significant in measuring fair value:
	Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
	Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models such as interest rates and yield curves that can be corroborated by observable market data.
	Level 3—Fair value is determined by using inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgment.
	Assets and liabilities subject to fair value measurements are as follows (in thousands):
			As of June 30, 2014
			Level 1			Level 2		Level 3		Balance
	Assets
	Money market funds (1)		$	153,410		$	—	$	—	$	153,410
	Federally-sponsored and corporate debt securities (2)		—			590,104		—		590,104
	Total assets		$	153,410		$	590,104	$	—	$	743,514
	Liabilities
	Convertible notes due 2016		$	456,905		$	—	$	—	$	456,905
	Contingent consideration (3)		—			—		4,777		4,777
	Total liabilities		$	456,905		$	—	$	4,777	$	461,682
			As of December 31, 2013
			Level 1			Level 2		Level 3		Balance
	Assets
	Money market funds (1)		$	145,194		$	—	$	—	$	145,194
	Federally-sponsored and corporate debt securities (2)		—			857,711		—		857,711
	Total assets		$	145,194		$	857,711	$	—	$	1,002,905
	Liabilities
	Convertible notes due 2016		$	593,750		$	—	$	—	$	593,750
	Contingent consideration (3)		—			—		6,616		6,616
	Total liabilities		$	593,750		$	—	$	6,616	$	600,366
		-1		Included in cash and cash equivalents on the accompanying consolidated balance sheets.
		-2		Included in current and non-current marketable investments on the accompanying consolidated balance sheets. The fair value of these securities is principally measured or corroborated by trade data for identical securities or comparable securities in which related trading activity is not sufficiently frequent to be considered a Level 1 input. See also Note 5—Investments—Marketable Investments—Held-to-Maturity Investments to these consolidated financial statements.
		-3		Included in other liabilities on the accompanying consolidated balance sheets. The fair value of contingent consideration has been estimated using probability weighted discounted cash flow models (DCF). The DCFs incorporate Level 3 inputs including estimated discount rates that we believe market participants would consider relevant in pricing and the projected timing and amount of cash flows, which are estimated and developed, in part, based on the requirements specific to each acquisition agreement. We analyze and evaluate these fair value measurements quarterly to determine whether valuation inputs continue to be relevant and appropriate or whether current period developments warrant adjustments to valuation inputs and related measurements. Any increases or decreases in discount rates would have an inverse impact on the corresponding fair value, while increases or decreases in expected cash flows would result in corresponding increases or decreases in fair value. As of both June 30, 2014 and December 31, 2013, the cost of debt and weighted average cost of capital used to discount projected cash flows relating to our contingent consideration ranged from 8.7 percent to 16.5 percent, respectively.
	A reconciliation of the beginning and ending balances of Level 3 liabilities for the three- and six-month periods ended June 30, 2014 is presented below (in thousands):
			Contingent
			Consideration
	Balance, April 1, 2014—Asset (Liability)		$	(5,943	)
	Transfers into Level 3		—
	Transfers out of Level 3		—
	Total gains/(losses) realized/unrealized:
	Included in earnings		1,149
	Included in other comprehensive income		17
	Purchases		—
	Sales		—
	Issuances		—
	Settlements		—
	Balance June 30, 2014—Asset (Liability)		$	(4,777	)
	Amount of total gains/(losses) for the three-month period ended June 30, 2014 included in earnings that are attributable to the change in unrealized gains or losses related to outstanding liabilities		$	1,149
			Contingent
			Consideration
	Balance January 1, 2014—Asset (Liability)		$	(6,616	)
	Transfers into Level 3		—
	Transfers out of Level 3		—
	Total gains/(losses) realized/unrealized:
	Included in earnings		1,132
	Included in other comprehensive income		23
	Purchases		—
	Sales		—
	Issuances		—
	Settlements		684
	Balance June 30, 2014—Asset (Liability)		$	(4,777	)
	Amount of total gains/(losses) for the six-month period ended June 30, 2014 included in earnings that are attributable to the change in unrealized gains or losses related to outstanding liabilities		$	1,132
	Fair Value of Financial Instruments
	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate fair value because of their short maturities. The fair values of our marketable investments and our Convertible Notes are reported above within the fair value hierarchy. The carrying value of our Wells Fargo mortgage loan and line of credit approximate fair value as both of these debt instruments bear a variable rate of interest that we believe approximates the market rate of interest for these instruments with similar credit risk profiles, terms and maturities (Level 2 in the fair value hierarchy). Refer to Note 9—Debt.

Investments

Investments	6 Months Ended
	Jun. 30, 2014
Investments	'
Investments	'
	5. Investments
	Marketable Investments
	Held-to-Maturity Investments
	Marketable investments classified as held-to-maturity consist of the following (in thousands):
	As of June 30, 2014	Amortized		Gross			Gross			Fair
		Cost		Unrealized			Unrealized			Value
				Gains			Losses
	Government-sponsored enterprises	$	243,013	$	253		$	(7	)	$	243,259
	Corporate notes and bonds	346,105		753			(13		)	346,845
	Total	$	589,118	$	1,006		$	(20	)	$	590,104
	Reported under the following captions on the consolidated balance sheet (1):
	Current marketable investments	$	308,534
	Noncurrent marketable investments	280,584
		$	589,118
	(1)Marketable investments include certain restricted current and non-current marketable investments of $46.8 million and $41.7 million, respectively, reflecting amounts pledged to secure the outstanding balance on our line of credit. Refer to Note 9—Debt—Line of Credit.
	As of December 31, 2013	Amortized		Gross			Gross			Fair
		Cost		Unrealized			Unrealized			Value
				Gains			Losses
	Government-sponsored enterprises	$	445,939	$	257		$	(77	)	$	446,119
	Corporate notes and bonds	411,455		300			(163		)	411,592
	Total	$	857,394	$	557		$	(240	)	$	857,711
	Reported under the following captions on the consolidated balance sheet (2):
	Current marketable investments	$	409,645
	Noncurrent marketable investments	447,749
		$	857,394
	(2)At December 31, 2013, none of our marketable investments were restricted.
	The following table summarizes gross unrealized losses and the length of time marketable investments have been in a continuous unrealized loss position (in thousands):
		As of June 30, 2014					As of December 31, 2013
		Fair		Gross			Fair			Gross
		Value		Unrealized			Value			Unrealized
				Loss						Loss
	Government-sponsored enterprises:
	Continuous unrealized loss position less than one year	$	13,258	$	(7	)	$	76,651		$	(77	)
	Continuous unrealized loss position greater than one year	—		—			—			—
		13,258		(7		)	76,651			(77		)
	Corporate notes and bonds:
	Continuous unrealized loss position less than one year	21,700		(13		)	168,669			(163		)
	Continuous unrealized loss position greater than one year	—		—			—			—
		21,700		(13		)	168,669			(163		)
	Total	$	34,958	$	(20	)	$	245,320		$	(240	)
	We attribute gross unrealized losses pertaining to our held-to-maturity securities as of June 30, 2014 and December 31, 2013 to the variability in related market interest rates. We do not intend to sell these securities, nor is it more likely than not that we will be required to sell them prior to the end of their contractual terms. Furthermore, we believe these securities do not expose us to undue market risk or counterparty credit risk. As such, we do not consider these securities to be other than temporarily impaired.
	The following table summarizes the contractual maturities of held-to-maturity marketable investments (in thousands):
		June 30, 2014
		Amortized		Fair
		Cost		Value
	Due in less than one year	$	308,534	$	308,792
	Due in one to two years	197,078		197,563
	Due in three to five years	83,506		83,749
	Due after five years	—		—
	Total	$	589,118	$	590,104
	Investments Held at Cost
	As of June 30, 2014, we maintain in the aggregate, non-controlling equity investments of $83.0 million in privately-held corporations, including a $50.0 million investment in preferred stock of Synthetic Genomics Inc. (SGI), which we purchased in May 2014. We account for these investments at cost since we do not have the ability to exercise significant influence over these companies and their fair values are not readily determinable. The fair value of these investments has not been estimated at June 30, 2014, as we have not identified any events or developments indicating that their carrying amounts may be impaired. We include these investments within other assets on our accompanying consolidated balance sheets.
	In addition to the investment noted above, we entered into a separate multi-year research and development collaboration agreement whereby SGI will develop engineered primary pig cells with modified genomes for use in our xenotransplantation program, which is principally focused on lungs.  Under this agreement, each party will assume its own research and development costs and SGI may receive royalties and milestone payments from the development and commercialization of organs.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2014
Goodwill and Other Intangible Assets	'
Goodwill and Other Intangible Assets	'
	6. Goodwill and Other Intangible Assets
	Goodwill and other intangible assets comprise the following (in thousands):
		As of June 30, 2014							As of December 31, 2013
		Gross		Accumulated			Net		Gross		Accumulated			Net
				Amortization							Amortization
	Goodwill (1)	$	10,666	$	—		$	10,666	$	10,703	$	—		$	10,703
	Other intangible assets (1):	—
	Technology, patents and trade names	7,008		(4,102		)	2,906		5,049		(3,730		)	1,319
	Customer relationships and non-compete agreements	4,905		(3,141		)	1,764		4,947		(2,886		)	2,061
	Contract-based	2,020		(2,020		)	—		2,020		(1,988		)	32
	Total	$	24,599	$	(9,263	)	$	15,336	$	22,719	$	(8,604	)	$	14,115
	(1)Includes foreign currency translation adjustments.

Supplemental_Executive_Retirem

Supplemental Executive Retirement Plan	6 Months Ended
	Jun. 30, 2014
Supplemental Executive Retirement Plan	'
Supplemental Executive Retirement Plan	'
	7. Supplemental Executive Retirement Plan
	We maintain the United Therapeutics Corporation Supplemental Executive Retirement Plan (SERP) to provide retirement benefits to certain senior members of our management team. To help fund our expected obligations under the SERP, we maintain the United Therapeutics Corporation Supplemental Executive Retirement Plan Rabbi Trust Document (Rabbi Trust). The balance in the Rabbi Trust was $5.1 million as of June 30, 2014 and December 31, 2013. The Rabbi Trust is irrevocable and SERP participants have no preferred claim on, nor any beneficial ownership interest in, any assets of the Rabbi Trust.
	Net periodic pension cost consists of the following (in thousands):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Service cost	$	1,379		$	1,352		$	2,758		$	2,703
	Interest cost	592			396			1,184			792
	Amortization of prior service cost	309			207			617			414
	Amortization of net actuarial loss	52			199			105			397
	Net pension expense	$	2,332		$	2,154		$	4,664		$	4,306
	Reclassifications related to the SERP from accumulated other comprehensive loss to the statement of operations by line item and the tax impact of these reclassifications is presented below (in thousands):
	Component Reclassified from Accumulated Other	Three Months Ended						Six Months Ended
		June 30,						June 30,
	Comprehensive Loss (1)	2014			2013			2014			2013
	Amortization of prior service cost:
	Research and development	$	102		$	79		$	204		$	155
	Selling, general and administrative	207			128			413			259
	Total	309			207			617			414
	Amortization of net actuarial loss:
	Research and development	17			75			35			149
	Selling, general and administrative	35			124			70			248
	Total	52			199			105			397
	Total amortization of prior service cost and net actuarial loss:	361			406			722			811
	Tax benefit	(126		)	(134		)	(253		)	(270		)
	Total, net of tax	$	235		$	272		$	469		$	541
	(1)Refer to Note 12—Accumulated Other Comprehensive Loss.

Share_Tracking_Award_Plans

Share Tracking Award Plans	6 Months Ended
	Jun. 30, 2014
Share Tracking Award Plans	'
Share Tracking Award Plans	'
	8. Share Tracking Award Plans
	We maintain the United Therapeutics Corporation Share Tracking Awards Plan, adopted in June 2008 (2008 STAP) and the United Therapeutics Corporation 2011 Share Tracking Awards Plan, adopted in March 2011 (2011 STAP). We refer to the 2008 STAP and the 2011 STAP collectively as the “STAP” and awards granted and/or outstanding under either of these plans as “STAP awards.” STAP awards convey the right to receive in cash an amount equal to the appreciation of our common stock, which is measured as the increase in the closing price of our common stock between the dates of grant and exercise. STAP awards generally vest in equal increments on each anniversary of the date of grant over a four-year period and expire on the tenth anniversary of the date of grant.
	The aggregate STAP liability balance was $181.2 million and $305.2 million at June 30, 2014 and December 31, 2013, respectively, of which $16.7 million and $17.2 million, respectively, have been classified as non-current liabilities under the caption “other liabilities” on our consolidated balance sheets based on their vesting terms.
	Estimating the fair value of STAP awards requires the use of certain inputs that can materially impact the determination of fair value and the amount of compensation expense (benefit) we recognize. Inputs used in estimating fair value include the price of our common stock, the expected volatility of the price of our common stock, the risk-free interest rate, the expected term of STAP awards, the expected forfeiture rate and the expected dividend yield. The fair value of the STAP awards is measured each financial reporting period because the awards are settled in cash.
	The table below includes the assumptions used to measure the fair value of STAP awards:
		June 30,		June 30,
		2014		2013
	Expected volatility	33.4	%	34.1	%
	Risk-free interest rate	1.1	%	1.1	%
	Expected term of awards (in years)	4.0		4.3
	Expected forfeiture rate	9.9	%	9.4	%
	Expected dividend yield	0.0	%	0.0	%
	A summary of the activity and status of STAP awards is presented below:
							Weighted
							Average
				Weighted-			Remaining		Aggregate
				Average			Contractual		Intrinsic
		Number of		Exercise			Term		Value
		Awards		Price			(in Years)		(in Thousands)
	Outstanding at January 1, 2014	8,734,901		$	52.75
	Granted	1,548,050		94.61
	Exercised	(1,187,854	)	49.27
	Forfeited	(130,664	)	62.63
	Outstanding at June 30, 2014	8,964,433		$	60.3		7.7		$	262,159
	Exercisable at June 30, 2014	3,514,810		$	50.85		6.2		$	132,292
	Expected to vest at June 30, 2014	4,903,029		$	66.63		8.6		$	115,775
	The weighted average grant-date fair value of STAP awards granted during the six-month periods ended June 30, 2014 and June 30, 2013 was $33.57 and $24.58, respectively.
	Share-based compensation (benefit) expense recognized in connection with the STAP is as follows (in thousands):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Research and development	$	928		$	14,069		$	(25,745	)	$	27,564
	Selling, general and administrative	(2,039		)	14,831			(34,011		)	29,761
	Cost of product sales	(1,038		)	239			(3,347		)	1,317
	Share-based compensation (benefit) expense before taxes	(2,149		)	29,139			(63,103		)	58,642
	Related income tax benefit (expense)	752			(9,674		)	22,086			(19,469		)
	Share-based compensation (benefit) expense, net of taxes	$	(1,397	)	$	19,465		$	(41,017	)	$	39,173
	Share-based compensation capitalized as part of inventory	$	826		$	53		$	562		$	323
	Cash paid to settle STAP awards exercised during the six-month periods ended June 30, 2014 and June 30, 2013 was $61.7 million and $24.5 million, respectively.

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt	'
Debt	'
	9. Debt
	Line of Credit
	In September 2013, we entered into a Credit Agreement with Wells Fargo Bank, National Association (Wells Fargo) providing us a $75.0 million revolving loan facility, which may be increased by up to an additional $75.0 million provided certain conditions are met (the 2013 Credit Agreement). At our option, amounts borrowed under the 2013 Credit Agreement bear interest at either the one-month LIBOR rate plus a 0.50 percent margin, or a fluctuating base rate excluding any margin. In addition, we are subject to a monthly commitment fee of 0.06 percent per annum on the average daily unused balance of the facility. Amounts borrowed under the 2013 Credit Agreement are secured by certain of our marketable investments.  As of June 30, 2014, we had an outstanding principal balance of $75.0 million under the 2013 Credit Agreement, which has been included under the caption “line of credit and mortgages payable—current” on our consolidated balance sheet. The outstanding balance is secured by $88.5 million in current and non-current marketable investments as noted in Note 5—Investments—Marketable Investments. We drew on the revolving loan facility, in part, to fund share repurchases during the second quarter of 2014. The 2013 Credit Agreement does not subject us to any financial covenants.  On July 24, 2014, we amended the 2013 Credit Agreement to extend its maturity date from September 26, 2014 to September 30, 2015.
	Convertible Notes Due 2016
	In October 2011, we issued $250.0 million in aggregate principal value 1.0 percent Convertible Senior Notes due September 15, 2016 (Convertible Notes). The Convertible Notes are unsecured, unsubordinated debt obligations that rank equally with all of our other unsecured and unsubordinated indebtedness. We pay interest semi-annually on March 15 and September 15 of each year. The initial conversion price is $47.69 per share and the number of underlying shares used to determine the aggregate consideration upon conversion is approximately 5.2 million shares.
	Conversion can occur: (1) any time after June 15, 2016; (2) during any calendar quarter that follows a calendar quarter in which the price of our common stock exceeds 130 percent of the conversion price for at least 20 days during the 30 consecutive trading-day period ending on the last trading day of the quarter; (3) during the ten consecutive trading-day period following any five consecutive trading-day period in which the trading price of the Convertible Notes is less than 95 percent of the closing price of our common stock multiplied by the then current number of shares underlying the Convertible Notes; (4) upon specified distributions to our shareholders; (5) in connection with certain corporate transactions; or (6) in the event that our common stock ceases to be listed on the NASDAQ Global Select Market, the NASDAQ Global Market or the New York Stock Exchange, or any of their respective successors.
	The closing price of our common stock exceeded 130 percent of the conversion price of the Convertible Notes for more than 20 trading days during the 30 consecutive trading day period ended June 30, 2014. Consequently, the Convertible Notes are convertible at the election of their holders. As this conversion right is outside of our control, the Convertible Notes are classified as a current liability on our consolidated balance sheet at June 30, 2014. We are required to calculate this contingent conversion provision at the end of each quarterly reporting period. Therefore, the convertibility and classification of our Convertible Notes may change depending on the price of our common stock.
	At June 30, 2014, the aggregate conversion value of the Convertible Notes exceeded their par value by $213.9 million using a conversion price of $88.49, the closing price of our common stock on June 30, 2014.
	Upon conversion, holders of our Convertible Notes are entitled to receive: (1) cash equal to the lesser of the par value of the notes or the conversion value (the number of shares underlying the Convertible Notes multiplied by the then current conversion price per share); and (2) to the extent the conversion value exceeds the par value of the notes, shares of our common stock. In the event of a change in control, as defined in the indenture under which the Convertible Notes have been issued, holders can require us to purchase all or a portion of their Convertible Notes for 100 percent of the notes’ par value plus any accrued and unpaid interest.
	The terms of the Convertible Notes provide for settlement wholly or partially in cash. Consequently, we are required to account for their liability and equity components separately so that the subsequent recognition of interest expense reflects our non-convertible borrowing rate. Accordingly, we estimated the fair value of the Convertible Notes without consideration of the conversion option as of the date of issuance (Liability Component). We recorded the excess of the proceeds received over the estimated fair value of the Liability Component totaling $57.9 million as the conversion option (Equity Component) and recognized a corresponding offset as a discount to the Convertible Notes to reduce their net carrying value. We reclassified a portion of the Equity Component equal to the unamortized discount as of June 30, 2014 to temporary equity because one of the contingent conversion criteria had been met at June 30, 2014, as disclosed above. Refer to Note 10—Temporary Equity. We are amortizing the debt discount over the five-year period ending September 15, 2016 (the expected life of the Liability Component) using the interest method and an effective rate of interest of 6.7 percent, which corresponded to our estimated non-convertible borrowing rate at the date of issuance.
	Interest expense incurred in connection with our convertible notes consisted of the following (in thousands):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014		2013
	Contractual coupon rate of interest	$	625		$	625		$	1,250	$	1,250
	Discount amortization	2,973			2,786			5,867		5,499
	Interest expense—convertible notes	$	3,598		$	3,411		$	7,117	$	6,749
	Components comprising the carrying value of the Convertible Notes include the following (in thousands):
		June 30,			December 31,
		2014			2013
	Principal balance	$	250,000		$	250,000
	Discount, net of accumulated amortization of $29,650 and $23,783	(28,288		)	(34,155		)
	Carrying amount	$	221,712		$	215,845
	Convertible Note Hedge and Warrant Transactions
	In connection with the issuance of our Convertible Notes, we entered into separate convertible note hedge and warrant transactions with Deutsche Bank AG London (DB London) to reduce the potentially dilutive impact of the conversion of our convertible notes. Pursuant to the convertible note hedge, we purchased call options to acquire up to approximately 5.2 million shares of our common stock with a strike price of $47.69. The call options become exercisable upon conversion of the Convertible Notes, and will terminate upon the maturity of the Convertible Notes or the first day the Convertible Notes are no longer outstanding, whichever occurs first. We also sold DB London warrants to acquire up to approximately 5.2 million shares of our common stock with a strike price of $67.56. The warrants will expire incrementally on a series of expiration dates subsequent to the maturity date of our Convertible Notes. Both the convertible note hedge and warrant transactions will be settled on a net-share basis. If the conversion price of our Convertible Notes is between the strike prices of the call options and warrants on the expiration dates of the warrants, our shareholders will not experience any dilution in connection with the conversion of our Convertible Notes; however, to the extent that the price of our common stock exceeds the strike price of the warrants on any or all of the series of related incremental expiration dates, we will be required to issue shares of our common stock to DB London.
	Mortgage Financing
	In December 2010, we entered into a Credit Agreement with Wells Fargo and Bank of America, N.A., pursuant to which we obtained a $70.0 million mortgage loan (the 2010 Credit Agreement). The 2010 Credit Agreement matures in December 2014 and is secured by certain of our facilities in Research Triangle Park, North Carolina and Silver Spring, Maryland. Annual principal payments are based on a twenty-five year amortization schedule using a fixed rate of interest of 7.0 percent and the outstanding debt bears a floating rate of interest per annum based on the one-month LIBOR, plus a credit spread of 3.75 percent, or approximately 3.91 percent as of June 30, 2014. We have the option to change the rate of interest charged on the loan to 2.75 percent plus the greater of: (1) Wells Fargo’s prime rate, or (2) the federal funds effective rate plus 0.05 percent, or (3) LIBOR plus 1.0 percent.  We can prepay the loan balance without being subject to a prepayment premium or penalty. As of June 30, 2014, the principal balance under the 2010 Credit Agreement was $66.5 million and is included within line of credit and mortgages payable—current as the outstanding balance will be due in December 2014. The 2010 Credit Agreement contains financial covenants, and as of June 30, 2014, we were in compliance with these covenants.

Temporary_Equity

Temporary Equity	6 Months Ended
	Jun. 30, 2014
Temporary Equity	'
Temporary Equity	'
	10. Temporary Equity
	Temporary equity includes securities that: (1) have redemption features that are outside our control; (2) are not classified as an asset or liability; (3) are excluded from permanent stockholders’ equity; and (4) are not mandatorily redeemable. Amounts included in temporary equity relate to securities that are redeemable at a fixed or determinable price.
	Components comprising the carrying value of temporary equity include the following (in thousands):
			June 30,		December 31,
			2014		2013
	Reclassification of Equity Component (1)		$	28,288	$	34,155
	Common stock subject to repurchase (2)		10,882		10,882
	Total		$	39,170	$	45,037
		-1		Represents the reclassification of the Equity Component equal to the unamortized debt discount of our Convertible Notes as of June 30, 2014 and December 31, 2013 from additional paid-in capital to temporary equity as our Convertible Notes were convertible at the election of their holders as noted above in Note 9—Debt—Convertible Notes Due 2016.
		-2		In connection with our amended 2007 agreement with Toray Industries Inc. (Toray), we issued 400,000 shares of our common stock and provided Toray the right to request that we repurchase the shares at a price of $27.21 per share.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity	'
Stockholders' Equity	'
	11. Stockholders’ Equity
	Earnings Per Common Share
	Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised.
	The components of basic and diluted earnings per common share comprised the following (in thousands, except per share amounts):
			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2014			2013			2014			2013
	Net income (numerator)		$	111,852		$	79,864		$	249,376		$	142,189
	Denominator:
	Weighted average outstanding shares — basic		47,617			49,800			49,002			50,003
	Effect of dilutive securities (1):
	Convertible notes (2)		2,643			1,362			2,721			1,120
	Warrants		1,560			—			1,671			—
	Stock options and employee stock purchase plan		1,432			1,486			1,554			1,263
	Weighted average shares — diluted		53,252			52,648			54,948			52,386
	Earnings per common share:
	Basic		$	2.35		$	1.60		$	5.09		$	2.84
	Diluted		$	2.10		$	1.52		$	4.54		$	2.71
	Stock options and warrants excluded from calculation (2)		9,925			10,485			9,814			11,026
		-1		Calculated using the treasury stock method.
		-2		Certain stock options and warrants were excluded from the computation of diluted earnings per share because their impact would be anti-dilutive. Under our convertible note hedge agreement, we are entitled to receive shares required to be issued to investors upon conversion of our Convertible Notes. Since related shares used to compute dilutive earnings per share would be anti-dilutive, they have been excluded from the calculation above.
	Stock Option Plan
	We may grant stock options to employees and non-employees under our equity incentive plan. We estimate the fair value of stock options using the Black-Scholes-Merton valuation model, which requires us to make certain assumptions that can materially impact the estimation of fair value and related compensation expense. These assumptions used to estimate fair value include the expected volatility of our common stock, the risk-free interest rate, the expected term of stock option awards and the expected dividend yield. We did not grant any stock options during the three- and six-month periods ended June 30, 2014 and 2013.
	A summary of the activity and status of employee stock options during the six-month period ended June 30, 2014 is presented below:
								Weighted
								Average
					Weighted-			Remaining		Aggregate
					Average			Contractual		Intrinsic
			Number of		Exercise			Term		Value
			Options		Price			(Years)		(in thousands)
	Outstanding at January 1, 2014		4,749,449		$	56.06
	Granted		—		—
	Exercised		(688,697	)	30.6
	Forfeited		(218	)	11.35
	Outstanding and exercisable at June 30, 2014		4,060,534		$	60.38		5.7		$	138,715
	Total share-based compensation expense related to employee stock options is as follows (in thousands):
			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2014			2013			2014			2013
	Selling, general and administrative		$	—		$	3,643		$	—		$	9,166
	Related income tax benefit		—			(1,209		)	—			(3,043		)
	Share-based compensation expense, net of taxes		$	—		$	2,434		$	—		$	6,123
	Employee and non-employee stock option exercise data is summarized below (dollars in thousands):
			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2014			2013			2014			2013
	Number of options exercised		445,955			205,323			717,197			354,690
	Cash received		$	13,736		$	5,838		$	22,171		$	10,097
	Employee Stock Purchase Plan
	In June 2012, our shareholders approved the United Therapeutics Corporation Employee Stock Purchase Plan (ESPP), which has been structured to comply with Section 423 of the Internal Revenue Code. The ESPP provides eligible employees the right to purchase shares of our common stock at a discount through elective accumulated payroll deductions at the end of each offering period. Offering periods occur in consecutive six-month periods commencing in September and March of each year. For the offering period ended in March 2014, we issued 26,534 shares of our common stock for $1.7 million in employee contributions. Eligible employees may contribute up to 15 percent of their base salary, subject to certain annual limitations as defined in the ESPP. The purchase price of the shares is equal to the lower of 85 percent of the closing price of our common stock on either the first or last trading day of a given offering period. In addition, the ESPP provides that no eligible employee may purchase more than 4,000 shares during any offering period. The ESPP has a 20-year term and limits the aggregate number of shares that can be issued to 3.0 million.
	Share-based compensation expense related to the ESPP for the three-month periods ended June 30, 2014 and 2013 was $276,500 and $202,600, respectively, and for the six-month periods ended June 30, 2014 and 2013 was $507,500 and $390,100, respectively.
	We estimate the fair value of the shares of our common stock to be purchased under the ESPP using the Black-Scholes-Merton model. Our approach in determining and estimating inputs for the ESPP is similar to the methodology we employ in valuing our STAP awards.
	Share Repurchases
	In February 2013, our Board of Directors authorized a share repurchase program for up to $420.0 million in aggregate repurchases of our common stock. We completed this repurchase program during the quarter ended June 30, 2014 and acquired 4.6 million shares of our common stock in the aggregate under the program.
	In addition, in June 2014, our Board of Directors authorized the repurchase of up to an additional $500.0 million of our common stock in open market or privately negotiated transactions, at our discretion.  This new program will become effective on August 1, 2014, and will remain open for up to one year.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Loss	'
Accumulated Other Comprehensive Loss	'
	12. Accumulated Other Comprehensive Loss
	The following table includes changes in accumulated other comprehensive income (loss) by component, net of tax (in thousands):
		Defined			Foreign			Unrealized
		Benefit			Currency			Losses on
		Pension			Translation			Available-for-
		Plan(1)			Gains			Sale Securities			Total
	Balance, January 1, 2014	$	(8,445	)	$	(5,069	)	$	331		$	(13,183	)
	Other comprehensive income (loss) before reclassifications	(2,194		)	382			(84		)	(1,896		)
	Amounts reclassified from accumulated other comprehensive loss	452			—			—			452
	Net current-period other comprehensive income (loss)	(1,742		)	382			(84		)	(1,444		)
	Balance, June 30, 2014	$	(10,187	)	$	(4,687	)	$	247		$	(14,627	)
	(1)Refer to Note 7—Supplemental Executive Retirement Plan which identifies the captions within our consolidated statement of operations where reclassification adjustments were recognized and their associated tax impact.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Taxes	'
Income Taxes	'
	13. Income Taxes
	Income tax expense for the three- and six-month periods ended June 30, 2014 and 2013 is based on the estimated effective tax rate for the entire year. The estimated annual effective tax rate can be subject to adjustment in subsequent quarterly periods if components used in its estimation are updated or revised. The estimated annual effective tax rates as of June 30, 2014 and 2013 were 35 percent and 33 percent, respectively.  Our 2014 estimated annual effective tax rate increased as of June 30, 2014 primarily due to a reduction in the amount of business tax credits we expect to generate during 2014 versus our estimate at June 30, 2013 for the 2013 tax year.
	We are subject to federal and state taxation in the United States and various foreign jurisdictions. Currently, our 2010 to 2012 tax years are subject to examination by the Internal Revenue Service and by state taxing authorities.
	We are unaware of any positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next 12 months.
	In September 2013, the Internal Revenue Service issued final regulations regarding the deduction and capitalization of expenditures related to tangible property. These final regulations apply to amounts paid to acquire, produce, or improve tangible property as well as dispositions of such property and are generally effective for tax years beginning on or after January 1, 2014. We have evaluated these regulations and determined they will not have a material impact on our consolidated results of operations, cash flows or financial position.

Segment_Information

Segment Information	6 Months Ended
	Jun. 30, 2014
Segment Information	'
Segment Information	'
	14. Segment Information
	We currently operate as one operating segment. However, our chief operating decision makers regularly review revenues, cost of product sales and gross profit data as the primary measures of performance for each of our four commercial products. We commenced sales of Orenitram during the second quarter of 2014.
	Net revenues, cost of product sales and gross profit for each of our commercial products were as follows (in thousands):
		Three Months Ended June 30,
	2014	Remodulin		Tyvaso		Adcirca		Orenitram		Total
	Net revenues	$	138,152	$	121,227	$	55,318	$	6,632	$	321,329
	Cost of product sales	14,381		18,744		3,389		2,195		38,709
	Gross profit	$	123,771	$	102,483	$	51,929	$	4,437	$	282,620
	2013
	Net revenues	$	124,311	$	109,458	$	43,726	$	—	$	277,495
	Cost of product sales	13,484		16,097		2,739		—		32,320
	Gross profit	$	110,827	$	93,361	$	40,987	$	—	$	245,175
		Six Months Ended June 30,
	2014	Remodulin		Tyvaso		Adcirca		Orenitram		Total
	Net revenues	$	274,259	$	228,313	$	96,678	$	6,632	$	605,882
	Cost of product sales	27,607		33,198		5,982		2,522		69,309
	Gross profit	$	246,652	$	195,115	$	90,696	$	4,110	$	536,573
	2013
	Net revenues	$	238,992	$	204,103	$	77,546	$	—	$	520,641
	Cost of product sales	26,890		29,880		4,863		—		61,633
	Gross profit	$	212,102	$	174,223	$	72,683	$	—	$	459,008
	For the three-month periods ended June 30, 2014 and 2013, net revenues from our U.S.-based distributors represented 75 percent and 77 percent, respectively, of our total net operating revenues.
	For the six-month periods ended June 30, 2014 and 2013, net revenues from our U.S.-based distributors represented 75 percent and 77 percent, respectively, of our total net operating revenues.

Litigation

Litigation	6 Months Ended
	Jun. 30, 2014
Litigation	'
Litigation	'
	15. Litigation
	Department of Health and Human Services Subpoena
	In December 2013, we received a subpoena from the Office of the Inspector General (OIG) of the Department of Health and Human Services reflecting a civil investigation by the United States Department of Justice, principally represented by the United States Attorney’s Office for the District of Maryland. The subpoena requests documents regarding Remodulin, Tyvaso and Adcirca, including our marketing practices relating to these products. We are cooperating with the investigation. We are not aware that a claim, litigation or assessment has been asserted in connection with the subpoena. However, we cannot predict what actions, if any, may be taken by the OIG, the Department of Justice, other governmental entities, or any third parties in connection with such investigation.
	Sandoz Inc.
	In February 2012, we received a Paragraph IV Certification Notice Letter (the Original Notice Letter) from Sandoz Inc. (Sandoz) advising that Sandoz had submitted an abbreviated new drug application (ANDA) to the FDA requesting approval to market a generic version of the 10 mg/mL strength of Remodulin.  In December 2012, we received notice (the Second Notice Letter) that Sandoz had amended its previously filed ANDA to request additional approval to market generic versions of the 1 mg/mL, 2.5 mg/mL, and 5 mg/mL strengths of Remodulin. In the Original Notice Letter and the Second Notice Letter, Sandoz stated that it intends to market a generic version of Remodulin before the expiration of the following patents relating to Remodulin: U.S. Patent No. 5,153,222, which expires in October 2014; U.S. Patent No. 6,765,117, which expires in October 2017; and U.S. Patent No. 7,999,007, which expires in March 2029.  Each of these patents is listed in the Orange Book.
	We responded to the Original Notice Letter by filing a lawsuit in March 2012 against Sandoz in the U.S. District Court for the District of New Jersey alleging patent infringement.  We responded to the Second Notice Letter by filing an additional lawsuit in January 2013 for patent infringement in the U.S. District Court for the District of New Jersey.  Sandoz filed counterclaims in each action alleging that the patents at issue in the litigation are invalid or will not be infringed by the commercial manufacture, use or sale of the proposed product described in Sandoz’s ANDA submission.  Shortly before trial, Sandoz withdrew its request to market a generic version of Remodulin before the expiration of U.S. Patent No. 5,153,222, but maintained its request to market a generic version of Remodulin before the expiration of the other two patents.  The trial for both lawsuits, limited to U.S. Patent Nos. 6,765,117 and 7,999,007, occurred in May and June 2014 and we are awaiting the Court’s decision.
	Under the Hatch-Waxman Act, the FDA is automatically precluded from approving Sandoz’s ANDA with respect to each concentration of Remodulin for up to 30 months from receipt of the Notice Letter corresponding to each concentration or until the issuance of a district court decision that is adverse to us, whichever occurs first.  We intend to vigorously enforce our intellectual property rights relating to Remodulin.

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventories	'
Schedule of inventories, net of reserves	'
	Inventories are stated at the lower of cost (first-in, first-out method) or market (current replacement cost) and consist of the following, net of reserves (in thousands):
		June 30,		December 31,
		2014		2013
	Raw materials	$	23,651	$	18,377
	Work-in-progress	12,027		11,802
	Finished goods	22,355		17,579
	Total inventories	$	58,033	$	47,758

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements	'
Schedule of assets and liabilities subject to fair value measurements	'
	Assets and liabilities subject to fair value measurements are as follows (in thousands):
			As of June 30, 2014
			Level 1			Level 2		Level 3		Balance
	Assets
	Money market funds (1)		$	153,410		$	—	$	—	$	153,410
	Federally-sponsored and corporate debt securities (2)		—			590,104		—		590,104
	Total assets		$	153,410		$	590,104	$	—	$	743,514
	Liabilities
	Convertible notes due 2016		$	456,905		$	—	$	—	$	456,905
	Contingent consideration (3)		—			—		4,777		4,777
	Total liabilities		$	456,905		$	—	$	4,777	$	461,682
			As of December 31, 2013
			Level 1			Level 2		Level 3		Balance
	Assets
	Money market funds (1)		$	145,194		$	—	$	—	$	145,194
	Federally-sponsored and corporate debt securities (2)		—			857,711		—		857,711
	Total assets		$	145,194		$	857,711	$	—	$	1,002,905
	Liabilities
	Convertible notes due 2016		$	593,750		$	—	$	—	$	593,750
	Contingent consideration (3)		—			—		6,616		6,616
	Total liabilities		$	593,750		$	—	$	6,616	$	600,366
		-1		Included in cash and cash equivalents on the accompanying consolidated balance sheets.
		-2		Included in current and non-current marketable investments on the accompanying consolidated balance sheets. The fair value of these securities is principally measured or corroborated by trade data for identical securities or comparable securities in which related trading activity is not sufficiently frequent to be considered a Level 1 input. See also Note 5—Investments—Marketable Investments—Held-to-Maturity Investments to these consolidated financial statements.
		-3		Included in other liabilities on the accompanying consolidated balance sheets. The fair value of contingent consideration has been estimated using probability weighted discounted cash flow models (DCF). The DCFs incorporate Level 3 inputs including estimated discount rates that we believe market participants would consider relevant in pricing and the projected timing and amount of cash flows, which are estimated and developed, in part, based on the requirements specific to each acquisition agreement. We analyze and evaluate these fair value measurements quarterly to determine whether valuation inputs continue to be relevant and appropriate or whether current period developments warrant adjustments to valuation inputs and related measurements. Any increases or decreases in discount rates would have an inverse impact on the corresponding fair value, while increases or decreases in expected cash flows would result in corresponding increases or decreases in fair value. As of both June 30, 2014 and December 31, 2013, the cost of debt and weighted average cost of capital used to discount projected cash flows relating to our contingent consideration ranged from 8.7 percent to 16.5 percent, respectively.
Schedule of reconciliations of the beginning and ending balances of Level 3 liabilities	'
	A reconciliation of the beginning and ending balances of Level 3 liabilities for the three- and six-month periods ended June 30, 2014 is presented below (in thousands):
			Contingent
			Consideration
	Balance, April 1, 2014—Asset (Liability)		$	(5,943	)
	Transfers into Level 3		—
	Transfers out of Level 3		—
	Total gains/(losses) realized/unrealized:
	Included in earnings		1,149
	Included in other comprehensive income		17
	Purchases		—
	Sales		—
	Issuances		—
	Settlements		—
	Balance June 30, 2014—Asset (Liability)		$	(4,777	)
	Amount of total gains/(losses) for the three-month period ended June 30, 2014 included in earnings that are attributable to the change in unrealized gains or losses related to outstanding liabilities		$	1,149
			Contingent
			Consideration
	Balance January 1, 2014—Asset (Liability)		$	(6,616	)
	Transfers into Level 3		—
	Transfers out of Level 3		—
	Total gains/(losses) realized/unrealized:
	Included in earnings		1,132
	Included in other comprehensive income		23
	Purchases		—
	Sales		—
	Issuances		—
	Settlements		684
	Balance June 30, 2014—Asset (Liability)		$	(4,777	)
	Amount of total gains/(losses) for the six-month period ended June 30, 2014 included in earnings that are attributable to the change in unrealized gains or losses related to outstanding liabilities		$	1,132

Investments_Tables

Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Investments	'
Schedule of marketable investments classified as held-to-maturity	'
	Marketable investments classified as held-to-maturity consist of the following (in thousands):
	As of June 30, 2014	Amortized		Gross			Gross			Fair
		Cost		Unrealized			Unrealized			Value
				Gains			Losses
	Government-sponsored enterprises	$	243,013	$	253		$	(7	)	$	243,259
	Corporate notes and bonds	346,105		753			(13		)	346,845
	Total	$	589,118	$	1,006		$	(20	)	$	590,104
	Reported under the following captions on the consolidated balance sheet (1):
	Current marketable investments	$	308,534
	Noncurrent marketable investments	280,584
		$	589,118
	(1)Marketable investments include certain restricted current and non-current marketable investments of $46.8 million and $41.7 million, respectively, reflecting amounts pledged to secure the outstanding balance on our line of credit. Refer to Note 9—Debt—Line of Credit.
	As of December 31, 2013	Amortized		Gross			Gross			Fair
		Cost		Unrealized			Unrealized			Value
				Gains			Losses
	Government-sponsored enterprises	$	445,939	$	257		$	(77	)	$	446,119
	Corporate notes and bonds	411,455		300			(163		)	411,592
	Total	$	857,394	$	557		$	(240	)	$	857,711
	Reported under the following captions on the consolidated balance sheet (2):
	Current marketable investments	$	409,645
	Noncurrent marketable investments	447,749
		$	857,394
	(2)At December 31, 2013, none of our marketable investments were restricted.
Summary of gross unrealized losses and the length of time marketable investments have been in a continuous unrealized loss position	'
	The following table summarizes gross unrealized losses and the length of time marketable investments have been in a continuous unrealized loss position (in thousands):
		As of June 30, 2014					As of December 31, 2013
		Fair		Gross			Fair			Gross
		Value		Unrealized			Value			Unrealized
				Loss						Loss
	Government-sponsored enterprises:
	Continuous unrealized loss position less than one year	$	13,258	$	(7	)	$	76,651		$	(77	)
	Continuous unrealized loss position greater than one year	—		—			—			—
		13,258		(7		)	76,651			(77		)
	Corporate notes and bonds:
	Continuous unrealized loss position less than one year	21,700		(13		)	168,669			(163		)
	Continuous unrealized loss position greater than one year	—		—			—			—
		21,700		(13		)	168,669			(163		)
	Total	$	34,958	$	(20	)	$	245,320		$	(240	)
Summary of the contractual maturities of held-to-maturity marketable investments	'
	The following table summarizes the contractual maturities of held-to-maturity marketable investments (in thousands):
		June 30, 2014
		Amortized		Fair
		Cost		Value
	Due in less than one year	$	308,534	$	308,792
	Due in one to two years	197,078		197,563
	Due in three to five years	83,506		83,749
	Due after five years	—		—
	Total	$	589,118	$	590,104

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Other Intangible Assets	'
Schedule of goodwill and other intangible assets	'
	Goodwill and other intangible assets comprise the following (in thousands):
		As of June 30, 2014							As of December 31, 2013
		Gross		Accumulated			Net		Gross		Accumulated			Net
				Amortization							Amortization
	Goodwill (1)	$	10,666	$	—		$	10,666	$	10,703	$	—		$	10,703
	Other intangible assets (1):	—
	Technology, patents and trade names	7,008		(4,102		)	2,906		5,049		(3,730		)	1,319
	Customer relationships and non-compete agreements	4,905		(3,141		)	1,764		4,947		(2,886		)	2,061
	Contract-based	2,020		(2,020		)	—		2,020		(1,988		)	32
	Total	$	24,599	$	(9,263	)	$	15,336	$	22,719	$	(8,604	)	$	14,115
	(1)Includes foreign currency translation adjustments.

Supplemental_Executive_Retirem1

Supplemental Executive Retirement Plan (Tables)	6 Months Ended
	Jun. 30, 2014
Supplemental Executive Retirement Plan	'
Schedule of components of net periodic pension cost recognized	'
	Net periodic pension cost consists of the following (in thousands):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Service cost	$	1,379		$	1,352		$	2,758		$	2,703
	Interest cost	592			396			1,184			792
	Amortization of prior service cost	309			207			617			414
	Amortization of net actuarial loss	52			199			105			397
	Net pension expense	$	2,332		$	2,154		$	4,664		$	4,306
Schedule of components reclassified from accumulated other comprehensive loss	'
	Reclassifications related to the SERP from accumulated other comprehensive loss to the statement of operations by line item and the tax impact of these reclassifications is presented below (in thousands):
	Component Reclassified from Accumulated Other	Three Months Ended						Six Months Ended
		June 30,						June 30,
	Comprehensive Loss (1)	2014			2013			2014			2013
	Amortization of prior service cost:
	Research and development	$	102		$	79		$	204		$	155
	Selling, general and administrative	207			128			413			259
	Total	309			207			617			414
	Amortization of net actuarial loss:
	Research and development	17			75			35			149
	Selling, general and administrative	35			124			70			248
	Total	52			199			105			397
	Total amortization of prior service cost and net actuarial loss:	361			406			722			811
	Tax benefit	(126		)	(134		)	(253		)	(270		)
	Total, net of tax	$	235		$	272		$	469		$	541
	(1)Refer to Note 12—Accumulated Other Comprehensive Loss.

Share_Tracking_Award_Plans_Tab

Share Tracking Award Plans (Tables) (Share Tracking Awards Plan [Member])	6 Months Ended
	Jun. 30, 2014
Share Tracking Awards Plan [Member]	'
Awards granted under the STAP	'
Schedule of assumptions to estimate the fair value of STAP awards	'
		June 30,		June 30,
		2014		2013
	Expected volatility	33.4	%	34.1	%
	Risk-free interest rate	1.1	%	1.1	%
	Expected term of awards (in years)	4.0		4.3
	Expected forfeiture rate	9.9	%	9.4	%
	Expected dividend yield	0.0	%	0.0	%
Summary of activity and status of STAP awards	'
							Weighted
							Average
				Weighted-			Remaining		Aggregate
				Average			Contractual		Intrinsic
		Number of		Exercise			Term		Value
		Awards		Price			(in Years)		(in Thousands)
	Outstanding at January 1, 2014	8,734,901		$	52.75
	Granted	1,548,050		94.61
	Exercised	(1,187,854	)	49.27
	Forfeited	(130,664	)	62.63
	Outstanding at June 30, 2014	8,964,433		$	60.3		7.7		$	262,159
	Exercisable at June 30, 2014	3,514,810		$	50.85		6.2		$	132,292
	Expected to vest at June 30, 2014	4,903,029		$	66.63		8.6		$	115,775
Schedule of share-based compensation (benefit) expense recognized in connection with the STAP	'
	Share-based compensation (benefit) expense recognized in connection with the STAP is as follows (in thousands):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Research and development	$	928		$	14,069		$	(25,745	)	$	27,564
	Selling, general and administrative	(2,039		)	14,831			(34,011		)	29,761
	Cost of product sales	(1,038		)	239			(3,347		)	1,317
	Share-based compensation (benefit) expense before taxes	(2,149		)	29,139			(63,103		)	58,642
	Related income tax benefit (expense)	752			(9,674		)	22,086			(19,469		)
	Share-based compensation (benefit) expense, net of taxes	$	(1,397	)	$	19,465		$	(41,017	)	$	39,173
	Share-based compensation capitalized as part of inventory	$	826		$	53		$	562		$	323

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Debt	'
Schedule of components of interest expense incurred in connection with the entity's convertible notes	'
	Interest expense incurred in connection with our convertible notes consisted of the following (in thousands):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014		2013
	Contractual coupon rate of interest	$	625		$	625		$	1,250	$	1,250
	Discount amortization	2,973			2,786			5,867		5,499
	Interest expense—convertible notes	$	3,598		$	3,411		$	7,117	$	6,749
Schedule of information about carrying amount of convertible notes	'
	Components comprising the carrying value of the Convertible Notes include the following (in thousands):
		June 30,			December 31,
		2014			2013
	Principal balance	$	250,000		$	250,000
	Discount, net of accumulated amortization of $29,650 and $23,783	(28,288		)	(34,155		)
	Carrying amount	$	221,712		$	215,845

Temporary_Equity_Tables

Temporary Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Temporary Equity	'
Schedule of components of temporary equity	'
	Components comprising the carrying value of temporary equity include the following (in thousands):
			June 30,		December 31,
			2014		2013
	Reclassification of Equity Component (1)		$	28,288	$	34,155
	Common stock subject to repurchase (2)		10,882		10,882
	Total		$	39,170	$	45,037
		-1		Represents the reclassification of the Equity Component equal to the unamortized debt discount of our Convertible Notes as of June 30, 2014 and December 31, 2013 from additional paid-in capital to temporary equity as our Convertible Notes were convertible at the election of their holders as noted above in Note 9—Debt—Convertible Notes Due 2016.
		-2		In connection with our amended 2007 agreement with Toray Industries Inc. (Toray), we issued 400,000 shares of our common stock and provided Toray the right to request that we repurchase the shares at a price of $27.21 per share.

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Common Share	'
Schedule of components of basic and diluted earnings per share	'
	The components of basic and diluted earnings per common share comprised the following (in thousands, except per share amounts):
			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2014			2013			2014			2013
	Net income (numerator)		$	111,852		$	79,864		$	249,376		$	142,189
	Denominator:
	Weighted average outstanding shares — basic		47,617			49,800			49,002			50,003
	Effect of dilutive securities (1):
	Convertible notes (2)		2,643			1,362			2,721			1,120
	Warrants		1,560			—			1,671			—
	Stock options and employee stock purchase plan		1,432			1,486			1,554			1,263
	Weighted average shares — diluted		53,252			52,648			54,948			52,386
	Earnings per common share:
	Basic		$	2.35		$	1.60		$	5.09		$	2.84
	Diluted		$	2.10		$	1.52		$	4.54		$	2.71
	Stock options and warrants excluded from calculation (2)		9,925			10,485			9,814			11,026
		-1		Calculated using the treasury stock method.
		-2		Certain stock options and warrants were excluded from the computation of diluted earnings per share because their impact would be anti-dilutive. Under our convertible note hedge agreement, we are entitled to receive shares required to be issued to investors upon conversion of our Convertible Notes. Since related shares used to compute dilutive earnings per share would be anti-dilutive, they have been excluded from the calculation above.
Employee Stock Option [Member]	'
Stock Option Plan	'
Schedule of stock option activity	'
	A summary of the activity and status of employee stock options during the six-month period ended June 30, 2014 is presented below:
								Weighted
								Average
					Weighted-			Remaining		Aggregate
					Average			Contractual		Intrinsic
			Number of		Exercise			Term		Value
			Options		Price			(Years)		(in thousands)
	Outstanding at January 1, 2014		4,749,449		$	56.06
	Granted		—		—
	Exercised		(688,697	)	30.6
	Forfeited		(218	)	11.35
	Outstanding and exercisable at June 30, 2014		4,060,534		$	60.38		5.7		$	138,715
Schedule of share-based compensation expense related to employee stock options	'
	Total share-based compensation expense related to employee stock options is as follows (in thousands):
			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2014			2013			2014			2013
	Selling, general and administrative		$	—		$	3,643		$	—		$	9,166
	Related income tax benefit		—			(1,209		)	—			(3,043		)
	Share-based compensation expense, net of taxes		$	—		$	2,434		$	—		$	6,123
Summary of employee and non-employee stock option exercise data	'
	Employee and non-employee stock option exercise data is summarized below (dollars in thousands):
			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2014			2013			2014			2013
	Number of options exercised		445,955			205,323			717,197			354,690
	Cash received		$	13,736		$	5,838		$	22,171		$	10,097

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Loss	'
Schedule of changes in accumulated other comprehensive income (loss) by component, net of tax	'
	The following table includes changes in accumulated other comprehensive income (loss) by component, net of tax (in thousands):
		Defined			Foreign			Unrealized
		Benefit			Currency			Losses on
		Pension			Translation			Available-for-
		Plan(1)			Gains			Sale Securities			Total
	Balance, January 1, 2014	$	(8,445	)	$	(5,069	)	$	331		$	(13,183	)
	Other comprehensive income (loss) before reclassifications	(2,194		)	382			(84		)	(1,896		)
	Amounts reclassified from accumulated other comprehensive loss	452			—			—			452
	Net current-period other comprehensive income (loss)	(1,742		)	382			(84		)	(1,444		)
	Balance, June 30, 2014	$	(10,187	)	$	(4,687	)	$	247		$	(14,627	)
	(1)Refer to Note 7—Supplemental Executive Retirement Plan which identifies the captions within our consolidated statement of operations where reclassification adjustments were recognized and their associated tax impact.

Segment_Information_Tables

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Information	'
Schedule of net revenues, cost of product sales and gross profit for each commercial product	'
	Net revenues, cost of product sales and gross profit for each of our commercial products were as follows (in thousands):
		Three Months Ended June 30,
	2014	Remodulin		Tyvaso		Adcirca		Orenitram		Total
	Net revenues	$	138,152	$	121,227	$	55,318	$	6,632	$	321,329
	Cost of product sales	14,381		18,744		3,389		2,195		38,709
	Gross profit	$	123,771	$	102,483	$	51,929	$	4,437	$	282,620
	2013
	Net revenues	$	124,311	$	109,458	$	43,726	$	—	$	277,495
	Cost of product sales	13,484		16,097		2,739		—		32,320
	Gross profit	$	110,827	$	93,361	$	40,987	$	—	$	245,175
		Six Months Ended June 30,
	2014	Remodulin		Tyvaso		Adcirca		Orenitram		Total
	Net revenues	$	274,259	$	228,313	$	96,678	$	6,632	$	605,882
	Cost of product sales	27,607		33,198		5,982		2,522		69,309
	Gross profit	$	246,652	$	195,115	$	90,696	$	4,110	$	536,573
	2013
	Net revenues	$	238,992	$	204,103	$	77,546	$	—	$	520,641
	Cost of product sales	26,890		29,880		4,863		—		61,633
	Gross profit	$	212,102	$	174,223	$	72,683	$	—	$	459,008

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventories:	'	'
Raw materials	$23,651	$18,377
Work-in-progress	12,027	11,802
Finished goods	22,355	17,579
Total inventories	$58,033	$47,758

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets	'	'
Federally-sponsored and corporate debt securities	$590,104	$857,711
Discounted Cash Flow Valuation Technique [Member] | Maximum [Member]	'	'
Liabilities	'	'
Cost of debt and weighted average cost of capital (as a percent)	16.50%	16.50%
Discounted Cash Flow Valuation Technique [Member] | Minimum [Member]	'	'
Liabilities	'	'
Cost of debt and weighted average cost of capital (as a percent)	8.70%	8.70%
Fair Value Measurements Recurring [Member] | Fair Value Inputs Level1 [Member]	'	'
Assets	'	'
Money market funds	153,410	145,194
Total assets	153,410	145,194
Liabilities	'	'
Convertible notes due 2016	456,905	593,750
Total liabilities	456,905	593,750
Fair Value Measurements Recurring [Member] | Fair Value Inputs Level2 [Member]	'	'
Assets	'	'
Federally-sponsored and corporate debt securities	590,104	857,711
Total assets	590,104	857,711
Fair Value Measurements Recurring [Member] | Fair Value Inputs Level3 [Member]	'	'
Liabilities	'	'
Contingent consideration	4,777	6,616
Total liabilities	4,777	6,616
Fair Value Measurements Recurring [Member] | Estimate Of Fair Value Fair Value Disclosure [Member]	'	'
Assets	'	'
Money market funds	153,410	145,194
Federally-sponsored and corporate debt securities	590,104	857,711
Total assets	743,514	1,002,905
Liabilities	'	'
Convertible notes due 2016	456,905	593,750
Contingent consideration	4,777	6,616
Total liabilities	$461,682	$600,366

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (Contingent Consideration [Member], USD $)	3 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014
Contingent Consideration [Member]	'	'
Reconciliation of beginning and ending balances of Level 3 assets and liabilities	'	'
Beginning balance	($5,943)	($6,616)
Total gains/(losses) realized/unrealized	'	'
Included in earnings	1,149	1,132
Included in other comprehensive income	17	23
Settlements	'	684
Ending balance	-4,777	-4,777
Amount of total gains/(losses) for the period included in earnings attributable to the change in unrealized gains or losses related to outstanding liabilities	$1,149	$1,132

Investments_Details

Investments (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Marketable investments classified as held-to-maturity:	'	'
Amortized Cost	$589,118,000	$857,394,000
Gross Unrealized Gains	1,006,000	557,000
Gross Unrealized Losses	-20,000	-240,000
Fair Value	590,104,000	857,711,000
Restricted marketable investments current	46,800,000	'
Restricted marketable investments non-current	41,700,000	'
Restricted marketable investments	'	0
U S Government Sponsored Enterprises Debt Securities [Member]	'	'
Marketable investments classified as held-to-maturity:	'	'
Amortized Cost	243,013,000	445,939,000
Gross Unrealized Gains	253,000	257,000
Gross Unrealized Losses	-7,000	-77,000
Fair Value	243,259,000	446,119,000
Corporate Debt Securities [Member]	'	'
Marketable investments classified as held-to-maturity:	'	'
Amortized Cost	346,105,000	411,455,000
Gross Unrealized Gains	753,000	300,000
Gross Unrealized Losses	-13,000	-163,000
Fair Value	$346,845,000	$411,592,000

Investments_Details_2

Investments (Details 2) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
As reported on the consolidated balance sheets:	'	'
Current marketable investments	$308,534	$409,645
Noncurrent marketable investments	280,584	447,749
Total marketable investments	$589,118	$857,394

Investments_Details_3

Investments (Details 3) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Continuous unrealized loss position, Fair Value	'	'
Fair Value, Total	$34,958	$245,320
Continuous unrealized loss position, Gross Unrealized Loss	'	'
Gross Unrealized Loss, Total	-20	-240
U S Government Sponsored Enterprises Debt Securities [Member]	'	'
Continuous unrealized loss position, Fair Value	'	'
Less than one year, Fair value	13,258	76,651
Fair Value, Total	13,258	76,651
Continuous unrealized loss position, Gross Unrealized Loss	'	'
Less than one year, Gross Unrealized Loss	-7	-77
Gross Unrealized Loss, Total	-7	-77
Corporate Debt Securities [Member]	'	'
Continuous unrealized loss position, Fair Value	'	'
Less than one year, Fair value	21,700	168,669
Fair Value, Total	21,700	168,669
Continuous unrealized loss position, Gross Unrealized Loss	'	'
Less than one year, Gross Unrealized Loss	-13	-163
Gross Unrealized Loss, Total	($13)	($163)

Investments_Details_4

Investments (Details 4) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Amortized Cost	'	'
Due in less than one year, Amortized Cost	$308,534	'
Due in one to two years, Amortized Cost	197,078	'
Due in three to five years, Amortized Cost	83,506	'
Total marketable investments	589,118	857,394
Fair Value	'	'
Due in less than one year, Fair Value	308,792	'
Due in one to two years, Fair Value	197,563	'
Due in three to five years, Fair Value	83,749	'
Fair Value	$590,104	$857,711

Investments_Details_5

Investments (Details 5) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Privately Held Corporations [Member]	'
Cost Method Investments	'
Cost Method Investments	$83
Synthetic Genomics Inc [Member]	'
Cost Method Investments	'
Cost Method Investments	$50

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill and other intangible assets	'	'
Goodwill, Gross	$10,666	$10,703
Goodwill, Net	10,666	10,703
Other intangible assets, Accumulated Amortization	-9,263	-8,604
Total intangible assets, Gross	24,599	22,719
Total intangible assets, Net	15,336	14,115
Technology Patents And Trade Names [Member]	'	'
Goodwill and other intangible assets	'	'
Other intangible assets, Gross	7,008	5,049
Other intangible assets, Accumulated Amortization	-4,102	-3,730
Other intangible assets, Net	2,906	1,319
Amortization relating to other intangible assets	'	'
Finite-Lived Intangible Assets, Net	2,906	1,319
Customer Relationships And Noncompete Agreements [Member]	'	'
Goodwill and other intangible assets	'	'
Other intangible assets, Gross	4,905	4,947
Other intangible assets, Accumulated Amortization	-3,141	-2,886
Other intangible assets, Net	1,764	2,061
Amortization relating to other intangible assets	'	'
Finite-Lived Intangible Assets, Net	1,764	2,061
Finite Lived Contract Based Intangible Assets [Member]	'	'
Goodwill and other intangible assets	'	'
Other intangible assets, Gross	2,020	2,020
Other intangible assets, Accumulated Amortization	-2,020	-1,988
Other intangible assets, Net	'	32
Amortization relating to other intangible assets	'	'
Finite-Lived Intangible Assets, Net	'	$32

Supplemental_Executive_Retirem2

Supplemental Executive Retirement Plan (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Supplemental Executive Retirement Plan Disclosure	'	'	'	'	'
Other Assets, Noncurrent	$103,699	'	$103,699	'	$58,637
Supplemental Employee Retirement Plan Defined Benefit [Member]	'	'	'	'	'
Supplemental Executive Retirement Plan Disclosure	'	'	'	'	'
Other Assets, Noncurrent	5,100	'	5,100	'	5,100
Components of net periodic pension cost	'	'	'	'	'
Service cost	1,379	1,352	2,758	2,703	'
Interest cost	592	396	1,184	792	'
Amortization of prior service cost	309	207	617	414	'
Amortization of net actuarial loss	52	199	105	397	'
Net pension expense	$2,332	$2,154	$4,664	$4,306	'

Supplemental_Executive_Retirem3

Supplemental Executive Retirement Plan (Details 2) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Reclassifications related to the SERP from accumulated other comprehensive loss to the statement of operations	'	'	'	'
Amortization of prior service cost	$309	$207	$617	$414
Amortization of net actuarial loss	52	199	105	397
Total amortization of prior service cost and net actuarial loss	361	406	722	811
Tax benefit	-126	-134	-253	-270
Total, net of tax	235	272	469	541
Research And Development Expense [Member]	'	'	'	'
Reclassifications related to the SERP from accumulated other comprehensive loss to the statement of operations	'	'	'	'
Amortization of prior service cost	102	79	204	155
Amortization of net actuarial loss	17	75	35	149
Selling General And Administrative Expenses [Member]	'	'	'	'
Reclassifications related to the SERP from accumulated other comprehensive loss to the statement of operations	'	'	'	'
Amortization of prior service cost	207	128	413	259
Amortization of net actuarial loss	$35	$124	$70	$248

Share_Tracking_Award_Plans_Det

Share Tracking Award Plans (Details) (Share Tracking Awards Plan [Member], USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Share Tracking Awards Plan [Member]	'	'	'
Awards granted under the STAP	'	'	'
Share-based awards, vesting period	'4 years	'	'
Grant expiration period from the grant date	'10 years	'	'
Aggregate STAP liability	$181,200,000	'	$305,200,000
Long term portion of STAP liability	16,700,000	'	17,200,000
Assumptions used to measure the fair value of STAP awards	'	'	'
Expected volatility (as a percent)	33.40%	34.10%	'
Risk-free interest rate (as a percent)	1.10%	1.10%	'
Expected term of awards	'4 years	'4 years 3 months 18 days	'
Expected forfeiture rate (as a percent)	9.90%	9.40%	'
Expected dividend yield (as a percent)	0.00%	0.00%	'
Share-based awards activity	'	'	'
Outstanding at the beginning of the period (in shares)	8,734,901	'	'
Granted (in shares)	1,548,050	'	'
Exercised (in shares)	-1,187,854	'	'
Forfeited (in shares)	-130,664	'	'
Outstanding at the end of the period (in shares)	8,964,433	'	'
Exercisable at the end of the period (in shares)	3,514,810	'	'
Expected to vest at the end of the period (in shares)	4,903,029	'	'
Share awards, Weighted-Average Exercise Price	'	'	'
Outstanding at the beginning of the period (in dollars per share)	$52.75	'	'
Granted (in dollars per share)	$94.61	'	'
Exercised (in dollars per share)	$49.27	'	'
Forfeited (in dollars per share)	$62.63	'	'
Outstanding at the end of the period (in dollars per share)	$60.30	'	'
Exercisable at the end of the period (in dollars per share)	$50.85	'	'
Expected to vest at the end of the period (in dollars per share)	$66.63	'	'
Share awards, Weighted Average Remaining Contractual Term	'	'	'
Outstanding at the end the period	'7 years 8 months 12 days	'	'
Exercisable at the end of the period	'6 years 2 months 12 days	'	'
Expected to vest at the end of the period	'8 years 7 months 6 days	'	'
Share awards, Aggregate Intrinsic Value	'	'	'
Outstanding at the end of the period (in dollars)	262,159,000	'	'
Exercisable at the end of the period (in dollars)	132,292,000	'	'
Expected to vest at the end of the period (in dollars)	$115,775,000	'	'
Awards granted during the period, weighted average grant date fair value (in dollars per share)	$33.57	$24.58	'

Share_Tracking_Award_Plans_Det1

Share Tracking Award Plans (Details 2) (Share Tracking Awards Plan [Member], USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based compensation (benefit) expense recognized in connection with the STAP	'	'	'	'
Share-based compensation (benefit) expense before taxes	($2,149,000)	$29,139,000	($63,103,000)	$58,642,000
Related income tax benefit (expense)	752,000	-9,674,000	22,086,000	-19,469,000
Share-based compensation expense, net of taxes	-1,397,000	19,465,000	-41,017,000	39,173,000
Share-based compensation capitalized as part of inventory	826,000	53,000	562,000	323,000
Cash payments on awards exercised during the period	'	'	61,700,000	24,500,000
Research And Development Expense [Member]	'	'	'	'
Share-based compensation (benefit) expense recognized in connection with the STAP	'	'	'	'
Share-based compensation (benefit) expense before taxes	928,000	14,069,000	-25,745,000	27,564,000
Selling General And Administrative Expenses [Member]	'	'	'	'
Share-based compensation (benefit) expense recognized in connection with the STAP	'	'	'	'
Share-based compensation (benefit) expense before taxes	-2,039,000	14,831,000	-34,011,000	29,761,000
Cost Of Sales [Member]	'	'	'	'
Share-based compensation (benefit) expense recognized in connection with the STAP	'	'	'	'
Share-based compensation (benefit) expense before taxes	($1,038,000)	$239,000	($3,347,000)	$1,317,000

Debt_Details

Debt (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

Share data in Millions, except Per Share data, unless otherwise specified

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Oct. 31, 2011

Jun. 30, 2014

Dec. 31, 2010

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Convertible Debt [Member]

Convertible Debt [Member]

Convertible Debt [Member]

Convertible Debt [Member]

Line Of Credit [Member]

Line Of Credit [Member]

Line Of Credit [Member]

Convertible Notes Due2016 [Member]

Convertible Notes Due2016 [Member]

Convertible Notes Due2016 [Member]

First Mortgage [Member]

First Mortgage [Member]

First Mortgage [Member]

First Mortgage [Member]

First Mortgage [Member]

First Mortgage [Member]

Maximum [Member]

One Month L I B O R [Member]

Wells Fargo Prime Rate [Member]

Federal Funds Effective Rate [Member]

One Month L I B O R [Member]

London Interbank Offered Rate L I B O R [Member]

Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

'

'

'

$75,000,000

'

'

'

'

'

'

'

'

'

'

'

Additional increase in borrowing capacity of the line of credit available at the entity's option

'

'

'

'

'

'

'

'

'

'

75,000,000

'

'

'

'

'

'

'

'

'

'

Debt, floating rate of interest basis

'

'

'

'

'

'

'

'

'

'

'

'one-month LIBOR

'

'

'

'

'

'

'

'one-month LIBOR

'

Debt, floating rate of interest, basis spread (as a percent)

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

3.75%

'

Unused commitment fee (as a percent)

'

'

'

'

'

'

'

'

'

0.06%

'

'

'

'

'

'

'

'

'

'

'

Outstanding amount

'

'

'

'

'

'

'

'

'

75,000,000

'

'

'

'

'

'

'

'

'

'

'

Security for current and non-current marketable investments

'

'

'

'

0

'

'

'

'

88,500,000

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Lines of Credit

'

'

75,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt, maturity term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'25 years

'

'

'

'

'

Debt aggregate principal value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000,000

'

'

'

'

'

'

Convertible Senior Notes, stated percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

Conversion price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

$88.49

'

$47.69

'

'

'

'

'

'

Convertible debt, number of shares into which convertible

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.2

'

'

'

'

'

'

Percentage of conversion price that the closing sales price of the entity's common stock must exceed in order to make the notes convertible

'

'

'

'

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

'

'

'

Minimum number of trading days within 30 consecutive trading days in which closing price of the entity's common stock must exceed conversion price for notes to be redeemable

'

'

'

'

'

'

'

'

'

'

'

'

'20 days

'

'

'

'

'

'

'

'

Trading-day period used to determine contingent conversion requirement on notes

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

Number of consecutive business days immediately after any five consecutive trading-day period during note measurement period

'

'

'

'

'

'

'

'

'

'

'

'

'10 days

'

'

'

'

'

'

'

'

Number of consecutive trading-days during which the trading price of the convertible notes must be less than a given percentage of the entity's stock price to be

'

'

'

'

'

'

'

'

'

'

'

'

'5 days

'

'

'

'

'

'

'

'

Percentage of trading price of the entity's common stock's closing price and the conversion rate, maximum

'

'

'

'

'

'

'

'

'

'

'

'

95.00%

'

'

'

'

'

'

'

'

Amount by which aggregate conversion value exceeded par value

'

'

'

'

'

'

'

'

'

'

'

'

213,900,000

'

'

'

'

'

'

'

'

Redemption price of convertible notes as a percentage of principal amount, due to change in control

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

Equity component

'

'

'

'

'

'

'

'

'

'

'

'

57,900,000

'

'

'

'

'

'

'

'

Amortization schedule

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

Effective interest rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

6.70%

'

'

'

'

'

'

'

'

Interest expense incurred in connection with the entity's convertible notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractual coupon rate of interest

'

'

'

'

'

625,000

625,000

1,250,000

1,250,000

'

'

'

'

'

'

'

'

'

'

'

'

Discount amortization

'

'

'

'

'

2,973,000

2,786,000

5,867,000

5,499,000

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense-convertible notes

'

'

'

'

'

3,598,000

3,411,000

7,117,000

6,749,000

'

'

'

'

'

'

'

'

'

'

'

'

Carrying amount related to convertible notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal balance

'

'

'

'

'

'

'

'

'

'

'

'

250,000,000

250,000,000

'

66,500,000

'

'

'

'

'

Convertible debt, discount to reduce net carrying value

'

'

'

'

'

'

'

'

'

'

'

'

-28,288,000

-34,155,000

'

'

'

'

'

'

'

Discount, accumulated amortization

'

'

'

'

'

'

'

'

'

'

'

'

29,650,000

23,783,000

'

'

'

'

'

'

'

Carrying amount

'

'

'

'

'

'

'

'

'

'

'

'

221,712,000

215,845,000

'

'

'

'

'

'

'

Mortgage Financing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Mortgage loan under credit agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70,000,000

'

'

'

'

Mortgage term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'25 years

'

'

'

'

'

Amortization schedule, fixed interest rate for calculation of principal payments (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.00%

'

'

'

'

'

Debt, floating rate of interest basis

'

'

'

'

'

'

'

'

'

'

'

'one-month LIBOR

'

'

'

'

'

'

'

'one-month LIBOR

'

Debt, floating rate of interest, basis spread (as a percent)

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

3.75%

'

Debt, interest rate at period end (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.91%

'

'

'

'

'

Debt, interest rate, alternative option (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.75%

'

'

'

'

'

Debt, interest rate, alternative option, basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Wells Fargo's prime rate

'federal funds effective rate

'

'LIBOR

Debt, interest rate, alternative option, spread over basis (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.05%

'

1.00%

Interest expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total interest expense

$4,746,000

$4,520,000

$9,356,000

$8,956,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt_Details_2

Debt (Details 2) (Convertible Notes Due2016 [Member])	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Sale of warrant	'
Share warrant, number of shares	5.2
Share warrant, exercise price (in dollars per share)	67.56
Call Option [Member]	'
Purchase of call options	'
Convertible note hedge, approximate number of shares that can be purchased	5.2
Convertible note hedge, exercise price (in dollars per share)	47.69

Temporary_Equity_Details

Temporary Equity (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Temporary equity	'	'
Total	$39,170	$45,037
Temporary Equity Convertible Note Due2016 [Member]	'	'
Temporary equity	'	'
Reclassification of Equity Component	28,288	34,155
Temporary Equity Common Stocks Subject To Repurchase [Member]	'	'
Temporary equity	'	'
Common stock subject to repurchase	$10,882	$10,882
Common stock issued (in shares)	400,000	'
Repurchase price (in dollars per share)	$27.21	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Numerator:	'	'	'	'
Net income	$111,852	$79,864	$249,376	$142,189
Denominator:	'	'	'	'
Weighted average outstanding shares - basic	47,617	49,800	49,002	50,003
Effect of dilutive securities:	'	'	'	'
Convertible notes (in shares)	2,643	1,362	2,721	1,120
Warrants (in shares)	1,560	'	1,671	'
Stock options and employee stock purchase plan (in shares)	1,432	1,486	1,554	1,263
Weighted average shares - diluted	53,252	52,648	54,948	52,386
Earnings per common share:	'	'	'	'
Basic (in dollars per share)	$2.35	$1.60	$5.09	$2.84
Diluted (in dollars per share)	$2.10	$1.52	$4.54	$2.71
Stock options and warrants excluded from calculation (in shares)	9,925	10,485	9,814	11,026

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock option activity	'	'	'	'
Exercised (in shares)	-445,955	-205,323	-717,197	-354,690
Employee Stock Option [Member]	'	'	'	'
Stock option activity	'	'	'	'
Outstanding at the beginning of the period (in shares)	'	'	4,749,449	'
Exercised (in shares)	'	'	-688,697	'
Forfeited (in shares)	'	'	-218	'
Outstanding at the end of the period (in shares)	4,060,534	'	4,060,534	'
Employee stock options, Weighted-Average Exercise Price	'	'	'	'
Outstanding at the beginning of the period (in dollars per share)	'	'	56.06	'
Exercised (in dollars per share)	'	'	30.6	'
Forfeited (in dollars per share)	'	'	11.35	'
Outstanding at the end of the period (in dollars per share)	60.38	'	60.38	'
Employee stock options, Weighted Average Remaining Contractual Term	'	'	'	'
Outstanding at the end the period	'	'	'5 years 8 months 12 days	'
Employee stock options, Aggregate Intrinsic Value	'	'	'	'
Outstanding at the end of the period (in dollars)	138,715	'	138,715	'

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013
			employee
Share-based compensation expense related to outstanding awards	'	'	'	'	'
Share-based compensation expense	'	'	($62,596,000)	'	$68,199,000
Employee Stock Option [Member]	'	'	'	'	'
Share-based compensation expense related to outstanding awards	'	'	'	'	'
Related income tax benefit	'	-1,209,000	'	'	-3,043,000
Share-based compensation expense, net of taxes	'	2,434,000	'	'	6,123,000
Employee Stock [Member]	'	'	'	'	'
Share-based compensation expense related to outstanding awards	'	'	'	'	'
Offering period	'	'	'6 months	'	'
Common stock issued in connection with ESPP (in shares)	'	'	'	26,534	'
Common stock issued in connection with ESPP, Amount	'	'	'	1,700,000	'
Maximum percentage of compensation employees may contribute for ESPP	15.00%	'	15.00%	'	'
Percentage of the lower of the fair market value of common stock on the first or last trading-day of a given offering period	'	'	85.00%	'	'
Number of eligible employees who may purchase more than four thousand shares during offering period	'	'	0	'	'
Maximum number of shares each eligible employees may purchase in any given offering period	'	'	4,000	'	'
Term of employee stock purchase plan	'	'	'20 years	'	'
Maximum number of shares authorized to be issued	3,000,000	'	3,000,000	'	'
Share-based compensation expense	276,500	202,600	507,500	'	390,100
Selling General And Administrative Expenses [Member] | Employee Stock Option [Member]	'	'	'	'	'
Share-based compensation expense related to outstanding awards	'	'	'	'	'
Share-based compensation expense before taxes	'	$3,643,000	'	'	$9,166,000

Stockholders_Equity_Details_4

Stockholders' Equity (Details 4) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee and non-employee stock option exercise data	'	'	'	'
Number of options exercised (in shares)	445,955	205,323	717,197	354,690
Cash received	$13,736	$5,838	$22,171	$10,097

Stockholders_Equity_Details_5

Stockholders' Equity (Details 5) (USD $)	0 Months Ended	3 Months Ended	6 Months Ended	1 Months Ended	6 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Aug. 01, 2014	Jun. 30, 2014	Jun. 30, 2014	Feb. 28, 2013	Jun. 30, 2014
				Share Repurchase Program2013 [Member]	Share Repurchase Program2013 [Member]
Stockholders' Equity	'	'	'	'	'
Authorized aggregate repurchases of common stock	'	'	$500	$420	'
Warrants (in shares)	'	1,560	1,671	'	4,600
Period over which shares may be purchased under share repurchase program	'1 year	'	'	'	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Loss (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Changes in accumulated other comprehensive income (loss), net of tax	'	'	'	'
Balance at the beginning of the period	'	'	($13,183)	'
Other comprehensive income (loss) before reclassifications	'	'	-1,896	'
Amounts reclassified from accumulated other comprehensive income	'	'	452	'
Other comprehensive gain (loss), net of tax	1,015	-152	-1,444	-2,158
Balance at the end of the period	-14,627	'	-14,627	'
Accumulated Defined Benefit Plans Adjustment [Member]	'	'	'	'
Changes in accumulated other comprehensive income (loss), net of tax	'	'	'	'
Balance at the beginning of the period	'	'	-8,445	'
Other comprehensive income (loss) before reclassifications	'	'	-2,194	'
Amounts reclassified from accumulated other comprehensive income	'	'	452	'
Other comprehensive gain (loss), net of tax	'	'	-1,742	'
Balance at the end of the period	-10,187	'	-10,187	'
Accumulated Translation Adjustment [Member]	'	'	'	'
Changes in accumulated other comprehensive income (loss), net of tax	'	'	'	'
Balance at the beginning of the period	'	'	-5,069	'
Other comprehensive income (loss) before reclassifications	'	'	382	'
Other comprehensive gain (loss), net of tax	'	'	382	'
Balance at the end of the period	-4,687	'	-4,687	'
Accumulated Net Unrealized Investment Gain Loss [Member]	'	'	'	'
Changes in accumulated other comprehensive income (loss), net of tax	'	'	'	'
Balance at the beginning of the period	'	'	331	'
Other comprehensive income (loss) before reclassifications	'	'	-84	'
Other comprehensive gain (loss), net of tax	'	'	-84	'
Balance at the end of the period	$247	'	$247	'

Income_Taxes_Details

Income Taxes (Details)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income Taxes	'	'
Estimated Annual Effective Income Tax Rate	35.00%	33.00%

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			segment
			product
Segment Information	'	'	'	'
Number of operating segments	'	'	1	'
Number of commercial products	'	'	4	'
Revenues, cost of revenues and gross profit	'	'	'	'
Net revenues	$321,329	$277,495	$605,882	$520,641
Cost of product sales	38,709	32,320	69,309	61,633
Gross profit	282,620	245,175	536,573	459,008
Remodulin [Member]	'	'	'	'
Revenues, cost of revenues and gross profit	'	'	'	'
Net revenues	138,152	124,311	274,259	238,992
Cost of product sales	14,381	13,484	27,607	26,890
Gross profit	123,771	110,827	246,652	212,102
Tyvaso [Member]	'	'	'	'
Revenues, cost of revenues and gross profit	'	'	'	'
Net revenues	121,227	109,458	228,313	204,103
Cost of product sales	18,744	16,097	33,198	29,880
Gross profit	102,483	93,361	195,115	174,223
Adcirca [Member]	'	'	'	'
Revenues, cost of revenues and gross profit	'	'	'	'
Net revenues	55,318	43,726	96,678	77,546
Cost of product sales	3,389	2,739	5,982	4,863
Gross profit	51,929	40,987	90,696	72,683
Orenitram [Member]	'	'	'	'
Revenues, cost of revenues and gross profit	'	'	'	'
Net revenues	6,632	'	6,632	'
Cost of product sales	2,195	'	2,522	'
Gross profit	$4,437	'	$4,110	'

Segment_Information_Details_2

Segment Information (Details 2) (Sales Revenue Goods Net [Member], Customer Concentration Risk [Member], U S Based Distributors [Member])	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Sales Revenue Goods Net [Member] | Customer Concentration Risk [Member] | U S Based Distributors [Member]	'	'	'	'
Segment Information	'	'	'	'
Concentration risk, percentage	75.00%	77.00%	75.00%	77.00%

Litigation_Details

Litigation (Details) (Pending Litigation [Member])	6 Months Ended
	Jun. 30, 2014
Pending Litigation [Member]	'
Litigation	'
Maximum period for which the FDA is automatically precluded from approving Sandoz's ANDA	'30 months